Adamas Pharmaceuticals Provides Review of 2014 and Previews

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers

EMERYVILLE, Calif., Jan. 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS ) today provided a recap of its 2014 achievements and a preview of its near-term priorities. Adamas, which develops new treatments for neurological disorders, utilizes its technology platform to improve the pharmacokinetic profiles of approved drugs, alone and in fixed-dose combinations. The company's diversified business model includes forming partnerships to improve existing brands and developing wholly owned products. Its partnership to improve existing brands, which is currently focused on Alzheimer's disease, is with Forest Laboratories, a subsidiary of Actavis plc. Adamas' wholly owned product portfolio includes ADS-5102, now in late-stage clinical development for levodopa-induced dyskinesia (LID), a movement disorder associated with Parkinson's disease.

"2014 was a pivotal year for Adamas, as we expanded the foundation of our business," said Gregory T. Went, Chairman and CEO. "With two approved products from our Actavis partnership and a comprehensive pivotal Phase 3 program for ADS-5102 ongoing, we expect to have an exciting and productive 2015."

Dr. Went continued, "Our robust technology platform, which enhances the pharmacokinetic properties of existing drugs, offers an approach to bring better medicines to patients more quickly. We look forward to maximizing the impact of our platform by completing our NDA-enabling studies for our first wholly owned product, expanding the indications under investigation, and commencing work on a new product line."

2014 Business Highlights

The 2014 business highlights were:

  • Announced completion of studies needed for the New Drug Application (NDA) filing of Namzaric™ by Forest, triggering a $40 million milestone payment to Adamas.
  • Reported Phase 2/3 data for ADS-5102, Adamas' proprietary long-acting capsule formulation of amantadine HCl, at multiple medical meetings. ADS-5102 met its primary endpoint in the Phase 2/3 trial and demonstrated statistically significant improvements in a number of key assessments of LID.
  • Completed its initial public offering, raising approximately $43 million.
  • Earned a $25 million milestone payment from Forest upon the FDA's acceptance of the NDA for Namzaric.
  • Initiated multiple Phase 3 studies for ADS-5102 in patients with Parkinson's disease who have LID. These studies will provide the foundation for an NDA filing.
    • EASE LID will enroll approximately 120 patients. The 26-week trial will assess the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. The primary endpoint is a reduction in LID.
    • EASE LID 3 will enroll approximately 70 patients. The 13-week trial will assess the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. The primary endpoint is a reduction in LID.
    • EASE LID 2 is an open-label safety study of ADS-5102 in Parkinson's disease patients with LID.
  • Secured eight additional US patents for its increasing intellectual property portfolio in neurological disorders. Adamas now has 22 issued US patents -- 13 for its memantine products (with two additional applications pending) and nine for its amantadine products (with 16 additional applications pending).
  • Received a $30 million milestone payment from Forest for the FDA approval of Namzaric, the fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor) for the treatment of moderate to severe dementia of the Alzheimer's type.

Upcoming Business Drivers

Adamas priorities are to:

  • Complete enrollment in the Phase 3 LID program. EASE LID is expected to finish enrolling patients in mid-year 2015, and EASE LID 3 is expected to finish enrolling patients in the second half of 2015.
  • Report top-line data for Phase 3 EASE LID study around year-end 2015.
  • Begin clinical testing in the first half of 2015 of a potential new indication for ADS-5102 selected from the following areas:
    • hypokinetic movement disorders, generally characterized by decreased bodily movement or muscle rigidity, such as walking and fatigue issues associated with multiple sclerosis and walking deficits following stroke;
    • hyperkinetic movement disorders similar to LID, generally characterized by abnormally heightened, sometimes uncontrollable, movements, such as Huntington's chorea, tardive dyskinesia, and Tourette's Syndrome; and
    • neuropsychiatric disorders, such as depression, Alzheimer's disease and traumatic brain injury.
  • Continue to build an intellectual property portfolio protecting its novel inventions.

About Adamas

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixed-dose combination products. Adamas is currently developing its lead wholly-owned product candidate, ADS-5102, for a complication of Parkinson's disease known as levodopa-induced dyskinesia, or LID, and is evaluating other potential indications. The company's portfolio also includes two FDA-approved products. The first is a fixed-dose combination product, Namzaric™, and the second is a controlled-release product, Namenda XR ®. Forest markets both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com .

Namenda XR ® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

Namzaric™ is a trademark of Actavis, Inc. or its affiliates.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "would," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Such statements contained in this press release include expectations regarding the Adamas' platform, potential product indications and opportunities, the initiation, enrollment and completion of clinical trials, the establishment of additional corporate partnering and the strength and expansion of our intellectual property portfolio. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to clinical and development activities of current and future products, delays in enrollment, the competitive environment and the effectiveness of the intellectual property portfolio, as well as risks relating to Adamas' business in general, see Adamas' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2014. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release.

For questions, please contact: Julie Wood Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3528

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 95

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 128

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 60

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 20

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 27

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading

Top 5 Most Recently Viewed Articles

Growing FPSO Market Set to Reach $174 Billion by 2031

Updated Category News Views 101

Insights into the Floating Production Storage Offloading Market The Floating Production Storage Offloading (FPSO) market is emerging as a cornerstone in the offshore oil and gas industry. As global oil demands continue to escalate, industries and stakeholders are directing their attention towards FPSO technologies, which combine production and storage capabilities to...

Continue Reading
3D Systems Corporation Faces Potential Securities Fraud Lawsuit

Updated Category News Views 207

Potential Securities Fraud Lawsuit Against 3D Systems Corporation Investors in 3D Systems Corporation have a significant opportunity as rumors of a securities fraud lawsuit surface. This potential lawsuit is connected to claims of misleading statements made by the company regarding its financial performance and market outlook. Overview of the Allegations According to...

Continue Reading
Latest Insights into the U.S. Real Estate Landscape Today

Updated Category News Views 368

Understanding Recent Trends in U.S. Real Estate In recent months, the real estate market in the United States has demonstrated some fascinating trends. Notably, many Americans are choosing to stay in their homes rather than moving. In fact, only 11% moved in a recent year, a stark contrast to historical figures where up to a third of the population changed residences...

Continue Reading
Venture Global, Inc. Investors Encouraged to Take Action Soon

Updated Category News Views 285

Important Deadlines for Venture Global, Inc. Investors Investors of Venture Global, Inc. should pay close attention to approaching deadlines related to an ongoing securities class action. Those who purchased stock pursuant to the company's initial public offering (IPO) that took place in early 2025 have significant rights that might not require any out-of-pocket expense....

Continue Reading
Vatn Systems Makes Strategic Acquisition to Boost AUV Tech

Updated Category News Views 160

Vatn Systems' Strategic Move to Enhance Underwater Technology In an exciting development for the defense technology sector, Vatn Systems has made a significant advancement by acquiring Crewless Marine. This decision is part of Vatn's strategy to improve its autonomous underwater vehicles (AUVs), highlighting the importance of acoustic capabilities in undersea warfare....

Continue Reading